News
Asianet Newsable on MSN13m
Eli Lilly’s Cancer Drug Demonstrates Better Effectiveness Than AbbVie’s In Late Stage Trial: Retail Believes In Holding The StockJaypirca had an overall response rate better than AbbVie’s Imbruvica in the study, meaning a higher percentage of patients ...
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback